Pharma companies to remain mum on CMS' initial offers next week for the first year of IRA negotiations
24 Jan 2024
One of the biggest (if not the single biggest) gripe that the pharma industry has with the Inflation Reduction Act is that it considers the price negotiation process, which kicks off with an initial offer from CMS to the biopharma companies on Feb. 1, to be nothing more than price setting.
The price-setting mantra has stuck ever since it became clear that the companies cannot afford to say no to whatever price the process ends on, as such a move would trigger steep fines, or even a loss of access to Medicare for all of their products.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.